Skip to Content

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

Treatment with a novel Cereblon E3 Ligase Modulator Agent, in Combination with Dexamethasone and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma, achieves an ORR of 73,7 %. In this MEDtalk Professor Paul G. Richardson presents the data, and results on how combination therapy shows immune-stimulatory effects in patients with Relapsed/Refractory Multiple Myeloma.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top